EJNMMI Research

Table 3 Patients with disconcordant miTNM stages

From: Intraindividual comparison of [⁶⁸ Ga]-Ga-PSMA-11 and [¹⁸F]-F-PSMA-1007 in prostate cancer patients: a retrospective single-center analysis

ΔmiTNM	Indication	ADT	GSC	RPx	RTX	PSA	Device	[¹⁸F]-F-PSMA-1007	[⁶⁸Ga]-Ga-PSMA-11	miTNM
T	BCR	Naive	6	No	Seeds	4.99	PET/CT	T0	TR	N0M0
	PS	Naive	8	No	No	13.80	PET/CT	T2u	T2m	N0M0
	BCR	Naive	9	Yes	No	1.98	PET/CT	TR	T0	N0M0
	BCR	Ended	7	Yes	Yes	2.04	PET/CT	TR	T0	N1M1a
	BCR	Naive	9	Yes	No	0.63	PET/CT	T0	TR	N1M0
N	BCR	Naive	7	Yes	Yes	3.09	PET/CT	N2	N1	TRM1c
	FU	Naive	7	Yes	No	4.40	PET/CT	N2	N1	T0M0
	PS	Naive	7	No	No	113.70	PET/CT	N2	N1	T3bM0
M	BCR	Naive	9	Yes	No	0.58	PET/CT	M1b	M0	T0N1

ADT, androgen depriving therapy; GSC, Gleason Score, RPx, radical prostatectomy RTx, radiotherapy, BCR, biochemical recurrence; PS, primary staging; FU, follow-up; T2u (unifocal) T2m (multifocal), TR (local recurrence). Clinical consensus was made on the bold stage

Back to article page